An introduction to A2M, a large protein found naturally in blood plasma: how it works, how it differs from PRP, and where the research is headed.
Alpha-2-macroglobulin (A2M) is a large glycoprotein found naturally in blood plasma. It is best known as a broad-spectrum protease inhibitor. Rather than targeting a single enzyme, it can capture a wide range of proteases, the enzymes that break down other proteins.1,2
Human A2M is a very large molecule: a tetramer of roughly 720 kDa, made of four identical subunits arranged as two disulfide-linked pairs. It is the largest non-antibody protein in human plasma.3 It also binds a number of cytokines and growth factors, including IL-1β, IL-6, PDGF and bFGF, and can modify their biological activity.1
Simplified schematic, not to scale. Native A2M measures about 21 × 18.5 × 15 nm.3
A2M doesn’t block a protease’s active site directly. It physically traps the enzyme, which is why one mechanism works across so many proteases.3,1
Cartilage breakdown in osteoarthritis is driven in part by catabolic enzymes. These include matrix metalloproteinases such as MMP-13, and the aggrecanases ADAMTS-4 and ADAMTS-5.6,7 Laboratory studies have shown that A2M can inhibit both groups. It traps ADAMTS-4 and ADAMTS-5 through its bait region, and it reduced IL-1–induced MMP-13 in human cartilage cells in a dose-dependent way.6,7
In both healthy individuals and patients with osteoarthritis, A2M levels were lower in joint fluid than in blood serum. In osteoarthritis, MMP-13 was higher in joint fluid than in serum. The researchers concluded that the A2M naturally present in an arthritic joint is not enough to inactivate the high levels of catabolic factors found there.7
That gap is what has driven interest in A2M. In rat models of post-traumatic osteoarthritis, A2M injected into the joint reduced MMP-13 in joint fluid and slowed cartilage degeneration.7,8 Clinical studies are now needed to determine whether these findings carry over to patients.
PRP and A2M concentrates start from the same blood draw. Centrifugation separates blood into layers: red blood cells at the bottom, a thin layer rich in platelets and white cells, and platelet-poor plasma (PPP) on top.4
PRP is made by concentrating the platelet-rich layer. The PPP is typically discarded once PRP has been prepared.4
A2M is typically concentrated from that PPP. Once PPP is obtained, it is passed through filters that remove water and smaller molecules while retaining large plasma proteins such as A2M. The result is a concentrated protein preparation made from the patient’s own plasma.4,9
Red blood cells are set aside in both preparations.
The two preparations have different compositions. In a 2026 study in horses, A2M preparations contained more A2M and lower growth factor levels than PRP.10 PRP concentrates platelets and the growth factors they carry, while an A2M concentrate focuses on large plasma proteins.
Laboratory and animal studies have given researchers good reason to keep studying A2M.6,7,8 Clinical research is still early, and the field is working to understand how these findings translate to patient care.11
More clinical trials and data need to be collected before treatment recommendations can be made, or before we can truly say A2M is making a difference for patients.
How much A2M is needed for a clinical effect.
When to administer it, and how often.
Which conditions and patients are most likely to benefit.
Whether symptom improvements last, and whether disease progression can be slowed.
A2M is a large protein, about 720 kDa, found naturally in blood plasma. It is best known as a broad-spectrum protease inhibitor: it traps a wide range of enzymes that break down other proteins.
PRP concentrates platelets and the growth factors they carry. An A2M concentrate focuses on large plasma proteins such as A2M, and is typically made from platelet-poor plasma, the fraction usually discarded after PRP is prepared.
After centrifugation separates blood into layers, the platelet-poor plasma is passed through filters that remove water and smaller molecules while retaining large plasma proteins such as A2M.
Native A2M measures about 21 by 18.5 by 15 nanometers. It has about 11 times the mass of albumin, the most abundant plasma protein, and a platelet is roughly 100 to 150 times wider.
In osteoarthritis, joint fluid contains relatively little A2M and elevated levels of cartilage-degrading enzymes. In laboratory and animal studies, A2M inhibited these enzymes and slowed cartilage degeneration.
Clinical research on A2M is still early. More clinical trials and data need to be collected before treatment recommendations can be made, or before we can truly say A2M is making a difference for patients.
Reach out to learn more about how Cervos can support you when it comes to protein concentrating.
Contact CervosThis page is provided for educational purposes only and is not medical advice. It summarizes published research and does not describe the indications for use of any Cervos product. Several of the studies cited were conducted in the laboratory or in animals, and their results may not translate to patients. Clinicians should consult the applicable Instructions for Use and regulations. Last reviewed November 2026.
Get product updates, clinical evidence, and event news from Cervos Medical.